NCT06611020 Adjuvant VaccInation After Conization for the Treatment for CervicAL Dysplasia
| NCT ID | NCT06611020 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
| Condition | Cervical Intraepithelial Neoplasia |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2020-01-01 |
| Primary Completion | 2025-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2020-01-01 with a primary completion date of 2025-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
HPV vaccination has emerged as a strategy to reduce the risk of recurrence oafter excisional treatment. However, only few data are aviable. In this trial the investigators aim to assess the role of HPV vaccination in women traeted for HPV-related lesions
Eligibility Criteria
Inclusion Criteria: * Treatment of HPV-related disease Exclusion Criteria: * Previous HPV vaccination
Contact & Investigator
Grazia Casadei, MD
PRINCIPAL INVESTIGATOR
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Frequently Asked Questions
Who can join the NCT06611020 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Cervical Intraepithelial Neoplasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06611020 currently recruiting?
Yes, NCT06611020 is actively recruiting participants. Contact the research team at giorgiobogani@yahoo.it for enrollment information.
Where is the NCT06611020 trial being conducted?
This trial is being conducted at Milan, Italy, Milan, Italy.
Who is sponsoring the NCT06611020 clinical trial?
NCT06611020 is sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. The principal investigator is Grazia Casadei, MD at Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. The trial plans to enroll 600 participants.